AC Immune SA (ACIU)
NASDAQ: ACIU · Real-Time Price · USD
2.790
+0.060 (2.20%)
At close: Mar 6, 2026, 4:00 PM EST
2.750
-0.040 (-1.43%)
After-hours: Mar 6, 2026, 7:04 PM EST
AC Immune Employees
As of December 31, 2024, AC Immune had 172 total employees, including 133 full-time and 39 part-time employees. The number of employees increased by 11 or 6.83% compared to the previous year.
Employees
172
Change (1Y)
11
Growth (1Y)
6.83%
Revenue / Employee
$31,878
Profits / Employee
-$524,035
Market Cap
276.05M
Employees Chart
Related Stocks
| Company Name | Employees |
|---|---|
| Cellectis | 222 |
| Coherus Oncology | 158 |
| Abeona Therapeutics | 136 |
| Silence Therapeutics | 116 |
| Enlivex | 71 |
| Cybin | 50 |
| ALX Oncology Holdings | 44 |
| Surrozen | 41 |
ACIU News
- 2 months ago - AC Immune: Maintaining 'Buy' Rating On Next Steps For ACI-7104.056 Development In PD - Seeking Alpha
- 3 months ago - AC Immune Trial Shows Early Signs Immunotherapy May Slow Parkinson's - Benzinga
- 3 months ago - AC Immune Positive Interim Phase 2 Data on ACI-7104.056 Support Potential Slowing of Progression of Parkinson's Disease - GlobeNewsWire
- 4 months ago - AC Immune Reports Third Quarter 2025 Financial Results and Provides a Corporate Update - GlobeNewsWire
- 4 months ago - First Characterization of a TDP-43 PET Tracer Published in Nature Communications Showing Potential of AC Immune's ACI-19626 in Precision Medicine - GlobeNewsWire
- 7 months ago - AC Immune Reports Second Quarter 2025 Financial Results and Provides a Corporate Update - GlobeNewsWire
- 11 months ago - AC Immune Reports First Quarter 2025 Financial Results and Provides a Corporate Update - GlobeNewsWire
- 1 year ago - AC Immune Reports Further Positive Interim Results from Phase 2 Trial of ACI-7104.056 Active Immunotherapy in Early Parkinson's Disease - GlobeNewsWire